bioRxiv preprint doi: https://doi.org/10.1101/2020.05.05.077867; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Type III interferons disrupt the lung epithelial barrier upon viral recognition. 2 3 Achille Broggi1,*, Sreya Ghosh1,*, Benedetta Sposito1,2,*, Roberto Spreafico3, Fabio Balzarini1,2, 4 Antonino Lo Cascio1,2, Nicola Clementi4, Maria De Santis5, Nicasio Mancini4,6, Francesca 5 Granucci2,7, Ivan Zanoni1,2,8,#. 6 7 8 1 Harvard Medical School, Boston Children’s Hospital, Division of Immunology, Boston, United 9 States. 10 2 Department of Biotechnology and Biosciences, University of Milano - Bicocca, Milan, Italy. 11 3 Institute for Quantitative and Computational Biosciences, University of California, Los Angeles, 12 United States. 13 4 Laboratory of Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan, 14 Italy. 15 5 Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center - IRCCS, 16 Rozzano, Italy. 17 6 IRCCS San Raffaele Hospital, Milan, Italy. 18 7 INGM-National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi" Milan, Italy. 19 8 Harvard Medical School, Boston Children’s Hospital, Division of Gastroenterology, Boston, 20 United States. 21 * Equal contribution 22 # Corresponding author:
[email protected] 23 24 25 26 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.05.077867; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.